Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults

Layegh, Pouran; Rahsepar, Sara; Rahsepar, Amir Ali

doi:10.4269/ajtmh.2011.10-0002

Cited by 24 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of other studies have yielded similar results. Layegh et al showed that systemic Glucantime® has a significantly lower efficacy in treating acute cutaneous leishmaniasis in children than in adults (22). In another study performed on L. viannia species, cutaneous treatment by systemic Glucantime® also had a clinically significant lower response in children when compared with the same regimen dosage and duration in adults (23).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Karamian

Bojd

Salehabadi

et al. 2015

Easter Mediterr Health J

View full text Add to dashboard Cite

With limited options to treat cutaneous leishmaniasis, constant monitoring of the rate of resistance to pentavalent antimony-based drugs is needed. This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. Smears from 150 patients showed that 141 patients were infected by L. tropica and 9 by L. major. In total, 141 patients with L. tropica infection completed Glucantime® treatment and follow-up; 63.8% were treated intralesionally and 36.2% by intramuscular administration. The overall success rate after one course of therapy with Glucantime ® was 96.5% (136/141), and all the failures (5/141) occurred with intramuscular injections. Statistical analysis showed a significant difference between the failure rates of intramuscular and intralesional injections. Children < 10 years old had a significantly higher failure rate than adults.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Karamian

Bojd

Salehabadi

et al. 2015

Easter Mediterr Health J

View full text Add to dashboard Cite

show abstract

“…The maximum daily dose of SbV for children under 12 years of age must not exceed 121.5mg (7.5ml), and treatment of children under 18 months is not recommended 39 . However, CL treatment with meglumine antimoniate is less effective in children than in adults [40][41][42] . The lower effi cacy may result from the pathogenicity of the parasite or the particular immune response of this age group 40,42 .…”

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 46(6):669-677, Nov-Dec, 2013http://dx.doi. org/10.1590/0037-8682-0104-2013 Address to: Dr a Juliana Saboia Fontenele e Silva. Lab. ABSTRACT We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fi ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.

show abstract

“…[5] Leishmaniasis is a diverse and complex disease. Each species can produce more than one clinical form of the disease and each form of the disease could be caused by multiple species.…”

Section: Discussion Discussionmentioning

confidence: 99%

“…L. tropica is capable of surviving in a latent state in previously affected tissues and may have spread after the cutaneous lesion healed. [12] Since mucosal involvement due to old-world leishmaniasis is not frequent and the few reported cases concern immunocompromised patients, [5] we assessed our patient in this respect. He had no signs of immunodeficiency.…”

Section: Discussion Discussionmentioning

confidence: 99%

Old-world leishmaniasis presenting as a nasal mass

Bakhshaee

Shahaboddin

Farzadnia

et al. 2014

Indian J Dermatol Venereol Leprol

Self Cite

View full text Add to dashboard Cite

Mucosal leishmaniasis is a major problem in Latin America but has been rarely noticed in our region. Although there have been a few reports of mucosal involvement especially in the oral cavity from Southwest Iran, yet none have been presented from the Northeast where Leishmania tropica is the major concern. We report a patient with endonasal leishmaniasis due to L. tropica, an extremely rare entity in immunocompetent patients in our region. He presented with a mass in the left nasal vestibule causing a sense of obstruction on the same side, accompanied by occasional rhinorrhea and mild epistaxis. This case exemplifies the need for considering leishmaniasis as a differential diagnosis for nasal obstruction in this endemic area.

show abstract

Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults

Cited by 24 publications

References 14 publications

Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Old-world leishmaniasis presenting as a nasal mass

Contact Info

Product

Resources

About